Scarica l'app Stockscreener
19.03
1.60%
0.30
Dopo l'orario di chiusura:
19.20
0.17
+0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value? - Simply Wall St
Wells Fargo Downgrades Viridian Therapeutics (VRDN) - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap DownTime to Sell? - MarketBeat
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
Wells Fargo & Company Reiterates "Equal Weight" Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by State Street Corp - Defense World
State Street Corp Has $54.14 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
When (VRDN) Moves Investors should Listen - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7%Here's What Happened - MarketBeat
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views - Benzinga
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics sees stock soar after Phase III TED success - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of Canada - MarketBeat
Viridian veers upwards on Phase III success - The Pharma Letter
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints - Yahoo Finance
Viridian Therapeutics' SWOT analysis: thyroid eye disease stock poised for growth - Investing.com India
Lord Abbett & CO. LLC Takes $8.92 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Wellington Management Group LLP Decreases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at HC Wainwright - Defense World
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap UpHere's What Happened - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Receives Buy Rating from HC Wainwright - MarketBeat
Viridian stock soars 25% on Phase 3 data for veligrotug (VRDN:NASDAQ) - Seeking Alpha
Viridian shares soar after latest trial success for thyroid eye disease drug - Reuters.com
Viridian Therapeutics (VRDN) Gains Momentum In Pre-Market Trading - Stocks Telegraph
Viridian Therapeutics Achieves Milestone in Phase 3 Trial - TipRanks
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Y Intercept Hong Kong Ltd Invests $660,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Exome Asset Management LLC Acquires New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
Viridian Therapeutics Enters Oversold Territory (VRDN) - Nasdaq
Point72 Asset Management L.P. Purchases Shares of 34,627 Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Two Sigma Advisers LP Cuts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
(VRDN) Technical Pivots with Risk Controls - Stock Traders Daily
Viridian Therapeutics' SWOT analysis: biotech stock poised for growth in TED market - Investing.com Nigeria
Polar Asset Management Partners Inc. Purchases 53,100 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
425,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Parkman Healthcare Partners LLC - MarketBeat
Viridian Therapeutics Awards Major Stock Options Package to Expand Team with 10 Key Hires - StockTitan
33,475 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Purchased by PDT Partners LLC - MarketBeat
Fmr LLC Has $254.42 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Walleye Capital LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Fisher Asset Management LLC Increases Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Great Point Partners LLC Has $17.06 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Algert Global LLC - MarketBeat
TD Cowen Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - MSN
Viridian Therapeutics' SWOT analysis: biotech firm's stock poised for growth in TED market - Investing.com
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
TD Cowen Initiates Coverage on Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
TD Cowen bullish on Viridian stock—veligrotug’s potential in TED drives optimism - Investing.com UK
Eagle Asset Management Inc. Reduces Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Principal Financial Group Inc. Purchases 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
B. Riley Forecasts Lower Earnings for Viridian Therapeutics - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):